Skip to main content
. 2018 Sep 10;7(11):1168–1177. doi: 10.1530/EC-18-0318

Figure 3.

Figure 3

Distribution of symptomatic patients (highly symptomatic, symptomatic, oligo symptomatic) among the different PPGL groups (A) and median plasma metanephrine (B) and normetanephrine levels (C) in relation to the symptom score.